ACS - Acute Coronary Syndrome
Conditions
Keywords
ACS, colchicine
Brief summary
The aim of this prospective cohort study was to investigate the multi-omics characteristics of the efficacy of colchicine treatment in patients with ACS and to construct a model of efficacy. The main questions the study aims to answer are \- Specific mechanisms of colchicine therapy in patients with ACS; Mechanism-based modelling to identify the population that benefits from colchicine treatment.
Interventions
Colchicine 0.5 MG Oral Tablet Once Daily
Sponsors
Shanghai Tongji Hospital, Tongji University School of Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Between the ages of 18 and 80 * ACS (STEMI or NSTE-ACS) * Patients to receive standardised drug therapy * Able and willing to provide informed consent
Exclusion criteria
* Any contraindication to colchicine or known intolerance to colchicine * Has been using colchicine for a prolonged period of time for other medical conditions * Women of childbearing age who are pregnant, breastfeeding or not using effective contraception * Coronary artery bypass grafting within the last 3 years or planned * Severe hepatic impairment: elevated serum alanine aminotransferase and/or aminotransferase (ALT) and/or aminotransferase (AST) levels of up to three times the upper limit of normal * Severe renal impairment: eGFR \<30mL/min/1.73m2 * Thrombocytopenia (platelet count less than 100\*10⁹/L) * Active diarrhoea * Infectious diseases: presence of uncontrollable infectious diseases * Immune-related diseases: known immune diseases such as systemic lupus erythematosus, asthma, inflammatory bowel disease, gout, malignant tumours, etc. * Strong CYP3A4 or P glycoprotein inhibitors (e.g., cyclosporine, antiretrovirals, antifungals, erythromycin and clarithromycin) are already in use and no alternative medications can be administered * Planning to use systemic anti-inflammatory therapies such as NSAIDs, hormones, immunomodulators and chemotherapeutic agents
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of responder | 6 months after enrolment | 1. Resolution of Inflammation: A reduction in high-sensitivity C-reactive protein (hs-CRP) levels to \<2.0 mg/L, or a decrease of ≥50% from baseline. 2. Clinical Stability: No occurrence of major adverse cardiovascular events (MACE), defined as cardiovascular death, non-fatal myocardial infarction, non-fatal ischemic stroke, or urgent revascularization. 3. Ventricular Remodeling: This is assessed by parameters such as ventricular volume, wall thickness, left ventricular mass, and LVEF (Left Ventricular Ejection Fraction), measured by cardiac magnetic resonance (CMR) or echocardiography. |
| Number of Participants with Advances in Coronary Artery Physiology and Function | 1 year after enrolment | Comparing the change in coronary QFR at baseline and one-year follow-up, the sum of QFR of the three major coronary vessels (anterior descending, circumflex, and right coronary artery) was calculated (3V-QFR), and progression in coronary physiology was defined when 3V-QFR minus baseline 3V-QFR at follow-up was ≤ -0.05 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of MACE within one year | 1 year after enrolment | MACE defined as: death (cardiac or non-cardiac), acute myocardial infarction, stroke, ischaemia-driven haemodialysis |
Countries
China
Contacts
Primary ContactXuebo Liu
Outcome results
None listed